PLAINSBORO, N.J., April 17, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the United States full market release of the Integra® Vu aPOD™ Prime Intervertebral Body Fusion Device (IBD), expanding Integra’s spine product portfolio with the addition of its first zero-profile, stand-alone IBD designed for anterior lumbar fusion (ALIF) procedures. The Integra® Vu aPOD™ Prime IBD has received 510(k) clearance from the United States Food & Drug Administration (FDA), and will be featured at the American Association of Neurological Surgeons annual meeting, April 14 - 18, 2012, in Miami, Florida.
